The diffusion-weighted magnetic resonance imaging (DWI) predicts the early response of esophageal squamous cell carcinoma to concurrent chemoradiotherapy

Esophageal carcinoma: Intravoxel incoherent motion diffusion‐weighted MRI parameters and histopathological correlations

“…Moreover, DWI can also be used as a potential biomarker in predicting the therapeutic effect during concurrent chemoradiotherapy and evaluating tumor aggressiveness. [28][29][30] These studies demonstrated that MR can be useful in tumor staging and in predicting prognosis.…”

“…Giganti et al reported that the use of MR with DWI showed the highest specificity (92%) and accuracy (83%) for T staging, and highest sensitivity (100%) and accuracy (66%) for N staging when compared with enhanced ultrasound and CT. Moreover, DWI can also be used as a potential biomarker in predicting the therapeutic effect during concurrent chemoradiotherapy and evaluating tumor aggressiveness . These studies demonstrated that MR can be useful in tumor staging and in predicting prognosis.…”

Role of intravoxel incoherent motion MRI in early assessment of the response of esophageal squamous cell carcinoma to chemoradiotherapy: A pilot study

“…DWI is able to measure water molecular diffusion quantified with apparent diffusion coefficient (ADC) values . ADC has potential in evaluating the curative effect of CRT in patients with esophageal cancer . However, if calculation of the DW‐derived ADC value is only acquired from two b values, the randomness becomes larger when fitting a line.…”

Surgical treatment of esophageal cancer in the era of multimodality management

“…37,[45][46][47][48] Several studies have been initiated to preoperatively identify these patients for an organ-preserving approach, avoiding unnecessary surgery-related morbidity, followed by active surveillance. In this light, various diagnostic strategies, such as endoscopic biopsies and/or EUS, 49 18F-FDG PET(-CT), 50,51 diffusion-weighted, [52][53][54][55] and dynamic contrast-enhanced 56 magnetic resonance imaging (MRI), are being researched to predict response and ultimately avoid surgery in selected patients. The MUNICON-1 and MUNICON-2 trials have shown that PET-based therapy individualization could be a feasible approach for GEJ adenocarcinomas.…”